To me, HFA means family. I’m beyond grateful to have such a strong network of support.

- Beth, hemophilia mother from Maine

### Financial Position

**Assets**
- Cash & Equivalents: $1,539,977
- Receivables: $1,584,383
- Investments: $2,253,490
- Other: $44,333
- **Total Assets**: $5,422,183

**Liabilities**
- Accounts Payable: $193,330
- Deferred Revenue: $1,399,480
- Other Liabilities: $38,591
- **Total Liabilities**: $1,631,401

**Net Assets**
- Net Assets: $3,668,014
- Temporarily Restricted: $122,768
- **Total Net Assets**: $3,790,782

**Total Liabilities & Net Assets**: $5,422,183

### Financial Highlights

**Revenue**
- Grants & Donations: $3,980,694
- Membership: $73,392
- Symposium: $681,350
- Informative Communications: $914,992
- Interest & Dividends: $63,886
- Change In Investment Values: $74,312
- **Total Assets**: $5,788,626

**Expenses**
- Program Services: $4,384,349
- Administrative: $189,575
- Fundraising: $108,620
- **Total Expenses**: $4,682,726

**Net Assets**
- Temporarily Restricted: $122,768
- **Total Net Assets**: $3,790,782

Our Impact:
- **$223,833** Distributed Through HFA’s Helping Hands Program
- **4,757** Attending Advocacy Sessions At Member Organizations
- **412** Served Through Helping Hands
- **1,104** Symposium Attendees
- **697** Active Blood Brothers
- **451** Active Blood Sisters
- **1,023** Adults In HFA’s Families Program
- **10,551** Community Members Served Through Programming

Thank You!

HFA thrives on the spirit and energy of community members from across the country and is able to assist, educate and advocate for so many due in part to the support of our corporate partners.

Accredo  BioMarin  Diploma  Accredo
Alnylam  Bioverativ  Genentech  NCHS
Aptevo  Colburn Keenan  Grifols  Novo Nordisk
ARJ Infusion  CSL Behring  HEMA Biologics  Octapharma
Bayer  CVS Specialty  Hemophilia Alliance  Option Care

www.hemophiliafed.org • 999 North Capitol Street • Suite 201 • Washington, D.C. 20002